Data as of Aug 29
| +0.34 / +1.58%|
The 6 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 32.50, with a high estimate of 41.00 and a low estimate of 23.00. The median estimate represents a +48.27% increase from the last price of 21.92.
The current consensus among 6 polled investment analysts is to Buy stock in Repros Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.